Picard Medical reports Q2 revenue $2.131M vs $694k last year

“Our second quarter results reflect strong sales growth for the SynCardia total artificial heart,” said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical (PMI). “We achieved over 200% revenue growth year-over-year, strengthened our operating profile, and successfully completed our IPO the proceeds of which provide us with the capital to advance development of our next-generation fully implantable heart and expand access to the SynCardia platform globally.”